Tech Company Financing Transactions
Invirsa Funding Round
Invirsa secured a $520 thousand Seed investment round on 11/8/2017. Investors included CincyTech and Rev1 Ventures.
Transaction Overview
Company Name
Announced On
11/8/2017
Transaction Type
Venture Equity
Amount
$520,000
Round
Seed
Investors
CincyTech (Lead Investor) (John Rice)
Rev1 Ventures (Margaret Groh)
Proceeds Purpose
This funding is the first step in bringing INV-102 into clinical development and ultimately to patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2807 Delmar Dr.
Columbus, OH 43209
USA
Columbus, OH 43209
USA
Phone
Undisclosed
Website
Email Address
Overview
Invirsa's lead compound, INV-102, is derived from a naturally occurring small molecule that modulates the activity of three parallel enzyme systems that are critical to innate immune response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Shalwitz
VP - Bus. Development
Isaiah Shalwitz
Browse more venture capital transactions:
Prev: 11/8/2017: VisitPay venture capital transaction
Next: 11/8/2017: Oyster Point Pharmaceuticals venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC transactions on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs